Company · Biotech and pharma
Melbourne, VIC
Every investor coverage indicates participated in a round Pathios Therapeutics raised.
Investors whose own portfolio pages list Pathios Therapeutics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
| Brandon Capital | its portfolio page ↗ |
Companies Pathios Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Stuart Hughes | Chief Executive Officer | biomelbourne.org, Brandon BioCatalyst portfolio |
| Paul G. Higham | Chief Executive Officer | Brandon BioCatalyst, Brandon Capital |
| Dr Tom McCarthy | Co-founder and Executive Chair | Brandon Capital, biomelbourne.org |
Stories naming Pathios Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.
Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.
Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.
UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.